Esophageal cancer is the eighth most common form of cancer world-wide and the sixth most common cause of cancer related death[@R1]. Esophageal adenocarcinoma (EAC) is the predominant subtype in the west, and incidence has been rapidly rising[@R2]. EAC is a highly aggressive neoplasm, usually presenting at a late stage, and is generally resistant to chemotherapy, leading to five-year survival rates below 15%[@R3]. It is characterized by very high mutation rates in comparison to other cancer types[@R4] but also, paradoxically, by a paucity of recurrently mutated genes. EAC displays dramatic chromosomal instability and thus may be classified as a C-type neoplasm, which may be driven mainly by structural variation rather than mutations[@R5],[@R6]. Currently, our understanding of precisely which genetic events drive the development of EAC is limited, and consequentially there is a paucity of molecular biomarkers for prognosis or targeted therapeutics available.

Methods to differentiate driver mutations from passenger mutations use features associated with known drivers to detect regions of the genome in which mutations are enriched for these features[@R7]. The simplest of these features is the tendency of a mutation to co-occur with other mutations in the same gene at a high frequency, as detected by MutSigCV[@R8]. MutSigCV has identified 12 known cancer genes as EAC drivers (*TP53*, *CDKN2A*, *SMAD4*, *ARID1A*, *ERBB2*, *KRAS*, *PIK3CA*, *SMARCA4*, *CTNNB1, ARID2, PBRM1* and *FBXW7*)[@R6],[@R9],[@R10]. The PCAWG ICGC analysis also identified a significantly mutated enhancer associated with *TP53TG1*[@R11]. However, these analyses leave most EAC cases with only one known driver mutation, usually *TP53*. Equivalent analyses in other cancer types have identified three or four drivers per case[@R12],[@R13]. Similarly, detection of copy number driver events in EAC has relied on identifying regions of the genome recurrently deleted or amplified, as detected by GISTIC[@R9],[@R14]--[@R17]. However, GISTIC often identifies relatively large regions of the genome, with little indication of which specific gene-copy number aberrations (CNAs) may actually confer a selective advantage. There are also several non-selection based mechanisms that can cause recurrent CNAs, such as genomic fragile sites, which have not been well differentiated from selection-based CNAs[@R18]. Epigenetic events, for example methylation, may also be important sources of driver events in EAC but are much more difficult to assess formally for selection.

To address these issues, we accumulated a cohort of 551 genomically characterized EACs using our esophageal ICGC project, which have high quality clinical annotation, associated whole genome sequencing (WGS) and RNA-seq on cases with sufficient material. We augmented our ICGC WGS cohort with publicly available whole exome[@R19] and whole genome sequencing[@R20] data and applied a number of complementary driver detection methods to produce a comprehensive assessment of mutations and CNAs under selection in EAC. We use these events to define functional cell processes that have been selectively dysregulated in EAC and identify novel, verifiable and clinically relevant biomarkers for prognostication. Finally, we have used this compendium of EAC driver events to provide an evidence base for targeted therapeutics, which we have tested *in vitro*.

Results {#S1}
=======

A compendium of EAC driver events and their functional impact {#S2}
-------------------------------------------------------------

In 551 EACs, we identified a total of 11,813,333 single nucleotide variants (SNVs) and small insertions or deletions (Indels), with a median of 6.4 such mutations/Mb ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), and 286,965 copy number aberrations (CNAs). We also identified 134,697 structural variants (SVs) in WGS cases. We use several complementary driver detection tools to detect driver-associated features in mutations and CNAs ([Fig. 1a](#F1){ref-type="fig"}). Each tool underwent quality control to ensure reliability of results (see [Methods](#S8){ref-type="sec"}). These features include highly recurrent mutations within a gene (dNdScv[@R21], ActivedriverWGS[@R22], MutSigCV2[@R8]), high functional impact mutations within a gene (OncodriveFM[@R23], ActivedriverWGS[@R22]), mutation clustering (OncodriveClust[@R24], eDriver[@R25] and eDriver3D[@R26]) and recurrent amplification or deletion of genes (GISTIC[@R14]) undergoing concurrent over or under-expression (see [Methods](#S8){ref-type="sec"}) ([Fig. 1a](#F1){ref-type="fig"})[@R7].

These complementary methods produced highly significant agreement in calling EAC driver genes, particularly within the same feature-type ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}), and on average more than half of the genes identified by one feature were also identified by other features ([Fig. 1b](#F1){ref-type="fig"}). In total, 76 EAC driver genes were discovered, 71% of which have not been detected in EAC previously[@R9],[@R10],[@R15]--[@R17],[@R19] and 69% of which are known drivers in pan-cancer analyses[@R21],[@R27],[@R28]. To detect driver elements in the non-coding genome, we used ActiveDriverWGS[@R22], a recently benchmarked[@R29] method using both functional impact and recurrence to determine driver status ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). We discovered 21 non-coding driver elements using this method. We have recovered several known non-coding driver elements from the pan-cancer PCAWG analysis[@R11], including the enhancer on chromosome 7 linked to *TP53TG1* previously identified in EAC and the promoter/5'UTR regions of *PTDSS1* and *WRD74* found in other cancer types. We also identified novel non-coding cancer driver elements, including in the 5'UTR of *MMP24* and promoters of two related histones (*HIST1H2BO* and *HIST1H2AM*).

EAC is notable among cancer types for harboring a high degree of chromosomal instability[@R20]. Using GISTIC, we identified 149 recurrently deleted or amplified loci across the genome ([Fig. 2a](#F2){ref-type="fig"}, and [Supplementary Tables 1 and 2](#SD1){ref-type="supplementary-material"}). To determine which genes within these loci confer a selective advantage when they undergo CNAs, we use a subset of 116 cases with matched RNA-seq to detect genes in which homozygous deletion or amplification causes a significant under or over-expression, respectively ([Supplementary Note and Supplementary Tables 3-6](#SD1){ref-type="supplementary-material"}). The majority of genes in these regions showed no significant copy number associated expression change (74%), although work in larger cohorts suggests we may be underpowered to detect small expression changes[@R30]. We observed highly significant expression changes in 17 known cancer genes within GISTIC loci such as *ERBB2*, *KRAS* and *SMAD4*, which we designate high-confidence EAC drivers (see [Methods](#S8){ref-type="sec"}). We also found five tumor suppressor genes where copy number loss was not necessarily associated with expression modulation but tightly associated with presence of mutations leading to LOH, for example *ARID1A* and *CDH11*.

In a subset of GISTIC loci, we observed extremely high copy number amplification, commonly greater than 100 copies, and these events were highly enriched in recurrently amplified regions containing driver genes rather than those which appear to contain only passengers (ploidy adjusted copy number \>10, two-sided Wilcoxon test, *P* = 4.97 x 10^-8^) ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). We use ploidy adjusted copy number to define amplifications as it produces superior correlation with expression data than absolute copy number alone. Ploidy of our samples varies from 1.4-6.2 (median 2.8), and hence ploidy adjusted copy number of \>10 cut off translates into \>14-62 absolute copies (on average 28 copies). To discern a mechanism for these ultra-high amplifications, we assessed structural variants (SVs) associated with these events. For many of these events, the extreme amplification was produced largely from a single copy number step, the edges of which were linked by structural variants with ultra-high read support. Two examples are shown in [Figure 2b](#F2){ref-type="fig"}, and further randomly selected examples in [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}. In the first example, circularization and amplification initially occurred around *MYC* but subsequently incorporated *ERBB2* from an entirely different chromosome, and in the second, an inversion was followed by circularization and amplification of *KRAS*. Such a pattern of extrachromosomal amplification via double minutes has been previously noted in EAC[@R20] and other neoplasms[@R31], and hence we refer to this amplification class with ultra-high amplification (ploidy adjusted copy number \>10) as 'extrachromosomal-like'.

We found that extrachromosomal-like amplifications had extreme and highly penetrant effects on expression, while moderate amplification (ploidy adjusted copy number \> 2 but \< 10) and homozygous deletion had highly significant (Wilcoxon test, two-sided, *P* = 9.62 x 10^-16^ and *P* = 7.64 x 10^-11^, respectively) but less dramatic effects on expression with a lower penetrance ([Fig. 2c](#F2){ref-type="fig"}). This lack of penetrance was associated with low cellularity as calculated by ASCAT (Wilcoxon test, two-sided, overexpression cut off = 2.5x normalised expression, *P* = 0.011) in non-extrachromosomal-like amplified cases but also likely reflects that specific genetic rearrangements, not just gene-dosage, can modulate expression. We also detected several cases of overexpression or complete expression loss without associated copy number changes, reflecting non-genetic mechanisms for driver dysregulation. One case overexpressed *ERBB2* at 28-fold median expression but had entirely diploid copy number in and surrounding *ERBB2*, and a second case lost *SMAD4* expression (0.008-fold median expression) despite possessing five copies of *SMAD4*.

Landscape of driver events in EAC {#S3}
---------------------------------

The overall landscape of driver gene mutations and copy number alterations per case is depicted in [Figure 3a](#F3){ref-type="fig"}. These comprise both oncogenes and tumor suppressor genes activated or repressed via different mechanisms. Passenger mutations occur by chance in most driver genes. To quantify this, we used the observed:expected mutation ratios (calculated by dNdScv) to estimate the percentage of driver mutations in each gene and in different mutation classes. For many drivers, only specific mutation classes appear to be under selection. Many tumor suppressor genes (*ARID2*, *RNF43*, *ARID1B* for example) are only under selection for truncating mutations, i.e. splice site, nonsense and frameshift Indel mutations, but not missense mutations, which are passengers. However, oncogenes, like *ERBB2*, only contain missense drivers that form clusters to activate gene function in a specific manner. Where a mutation class is \<100% driver mutations, mutational clustering can help us define the driver vs. passenger status of a mutation ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). Mutational hotspots in EAC or other cancer types[@R32] ([Supplementary Table 7 and Supplementary Data](#SD1){ref-type="supplementary-material"}) are indicated in [Figure 3a](#F3){ref-type="fig"}. Novel EAC drivers of particular interest include *B2M*, a core component of the MHC class I complex and a marker of acquired resistance to immunotherapy[@R33], *MUC6*, a secreted glycoprotein involved in gastric acid resistance, and *ABCB1*, a channel pump protein associated with multiple instances of drug resistance[@R34]. We note that several of these drivers have been previously associated with gastric and colorectal cancer ([Supplementary Table 8](#SD1){ref-type="supplementary-material"})[@R13],[@R35].

The identification of driver events provides rich information about the molecular history of each EAC tumor. We detect a median of five events in driver genes per tumor (IQR = 3-7, mean = 5.6), and only a very small fraction of cases has no such events detected (6 cases, 1%). When we remove the predicted percentage of passenger mutations using observed:expected mutation ratios calculated by dNdScv, one of the driver gene detection methods used, we find a mean of 4.4 true driver events per case. These derive more commonly from mutations than copy number events ([Fig. 3b](#F3){ref-type="fig"} and [Supplementary Table 9](#SD1){ref-type="supplementary-material"}). Using hierarchal clustering of drivers, we noted that *TP53* mutant cases had significantly more copy number drivers (Wilcoxon test, two-sided, *P* = 0.0032, [Supplementary Figs. 7 and 8](#SD1){ref-type="supplementary-material"}). dNdScv also analyses the genome-wide excess of non-synonymous mutations based on dN/dS ratios to assess the mean number of exonic driver mutations per case. This is calculated at 5.4 (95% CIs: 3.5-7.3) in comparison to a mean excess of 2.7 driver mutations in specific EAC driver genes, suggesting further low frequency driver genes are yet to be discovered in EAC.

To better understand the functional impact of driver mutations, we analyzed expression of driver genes with different mutation types and compared their expression to normal tissue RNA ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). Since surrounding squamous epithelium is a fundamentally different tissue from which EAC does not directly arise, we have used duodenum and gastric cardia samples as gastrointestinal phenotype controls, likely to be similar to the, as yet unconfirmed, tissue of origin in EAC. A large number of driver genes have upregulated expression in comparison to normal controls; for example, *TP53* has upregulated RNA expression in wild-type tumor tissue and in cases with non-truncating mutations but RNA expression is lost upon gene truncation. In depth analysis of different *TP53* mutation types reveals significant heterogeneity within non-truncating mutations ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). Normal tissue expression of *CDKN2A* suggests that *CDKN2A* is generally activated in EAC, likely due to genotoxic or other cancer-associated cellular stresses[@R36], and returns to physiologically normal levels when deleted. Heterogeneous expression in wild-type *CDKN2A* cases suggests a different mechanism of inhibition, perhaps methylation, in some cases. Overexpression of some oncogenes occurs without genomic aberrations, such as *MYC*, which is overexpressed in *MYC*-wild-type EACs relative to normal tissues ([Fig. 3c](#F3){ref-type="fig"}). A smaller number of driver genes are downregulated in EACs without genomic aberrations. 3/4 of these genes (*GATA4*, *GATA6* and *MUC6*) are involved in the differentiated phenotype of gastrointestinal tissues and may be lost with tumor de-differentiation.

Dysregulation of specific pathways and processes in EAC {#S4}
-------------------------------------------------------

It is known that selection preferentially dysregulates certain functionally related groups of genes and biological pathways in cancer[@R37]. This phenomenon is highly evident in EAC, as shown in [Figure 4](#F4){ref-type="fig"}, which depicts the functional relationships between EAC drivers ([Supplementary Note](#SD1){ref-type="supplementary-material"}). While *TP53* is the dominant driver in EAC, 28% of cases remain *TP53* wild-type. MDM2 is a E3 ubiquitin ligase that targets TP53 for degradation. Its selective amplification and overexpression is mutually exclusive with *TP53* mutation, suggesting it can functionally substitute the effect of *TP53* mutation via its degradation. Similar mutually exclusive relationships are observed between *KRAS* and *ERBB2*, *GATA4* and *GATA6*, and cyclin genes (*CCNE1*, *CCND1* and *CCND3*). Activation of the Wnt pathway occurs in 19% of cases either by mutation of phospho-residues at the N terminus of β-catenin, which prevent degradation, or loss of Wnt destruction complex components like APC. Many different chromatin modifying genes, often belonging to the SWI/SNF complex, are also selectively mutated (28% of cases). In contrast to other pathways, SWI/SNF genes are co-mutated significantly more often than we would expect by chance (Fisher's exact test, two-sided, *q* \< 0.05 for each gene; see [Methods](#S8){ref-type="sec"}), suggesting these mutations are synergistic. We also assessed mutual exclusivity and co-occurrence in genes in different pathways and between pathways themselves ([Fig. 4b](#F4){ref-type="fig"}). Of particular note are co-occurring relationships between *TP53* and *MYC*, *GATA6* and *SMAD4*, and Wnt and immune pathways, as well as mutually exclusive relationships between *ARID1A* and *MYC*, gastrointestinal (GI) differentiation and RTK pathways, and SWI-SNF and DNA damage response pathways. We were able to confirm some of these relationships in independent cohorts in different cancer types ([Supplementary Table 10](#SD1){ref-type="supplementary-material"}), suggesting some of these may be pan-cancer phenomenon. Wnt dysregulation was associated with hyper-mutated cases (\> 500 exonic SNVs or Indels, Fisher's exact test, two-sided, *P* = 2.98 x 10^-5^, OR = 9.3), as was mutation in immune pathway genes (*B2M* and *JAK1*, \> 500 exonic SNVs or Indels, Fisher's exact test, two-sided, *P* = 6.27 x 10^-6^, OR = 35.7).

EAC driver events correlate with clinical phenotype {#S5}
---------------------------------------------------

Events undergoing selection during cancer evolution influence tumor biology and thus impact tumor aggressiveness, response to treatment, and patient prognosis, as well as other clinical parameters.

Univariate Cox regression was performed for events in each driver gene with driver events occurring in greater than 5% of EACs after passenger removal to detect prognostic biomarkers ([Fig. 5a](#F5){ref-type="fig"}). Events in two genes conferred significantly poorer prognosis after multiple hypothesis correction: *GATA4* amplification (HR = 0.54, 95% CI = 0.38--0.78, *P* = 0.0008) and *SMAD4* mutation or homozygous deletion (HR = 0.60, 95% CI = 0.42--0.84, *P* = 0.003), which were present in 31% of EACs ([Fig. 5b](#F5){ref-type="fig"}). Both genes remained significant in multivariate Cox regression, including pathological TNM staging, resection margin, curative vs. palliative treatment intent, and differentiation status (*GATA4*, HR adjusted = 0.47, 95% CIs adjusted = 0.29--0.76, *P* = 0.002; *SMAD4*, HR adjusted = 0.61, 95% CI adjusted = 0.40--0.94, *P* = 0.026) ([Fig. 5b](#F5){ref-type="fig"}, [Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}). We validated the poor prognostic impact of *SMAD4* events in an independent TCGA gastroesophageal cohort (HR = 0.58, 95% CI = 0.37--0.90, *P* = 0.014) ([Fig. 5c](#F5){ref-type="fig"}), and we also found *GATA4* amplifications were prognostic in a cohort of TCGA pancreatic cancers (HR = 0.38, 95% CI = 0.18--0.80, *P* = 0.011) ([Fig. 5d](#F5){ref-type="fig"}), the only available cohort containing a feasible number of *GATA4* amplifications. The prognostic impact of *GATA4* has been suggested in previously published independent EAC cohort[@R16], although it did not reach statistical significance after FDR correction, and SMAD4 expression loss has been previously linked to poor prognosis in EAC[@R38]. We also noted stark survival differences between cases with *SMAD4* events and cases in which TGFβ receptors were mutated ([Fig. 5e](#F5){ref-type="fig"}, HR = 5.6, 95% CI = 1.7--18.2, *P* = 0.005), in keeping with the biology of the TGFβ pathway, where non-SMAD TGFβ signalling is known to be oncogenic[@R39].

In additional to survival analyses, we also assessed driver gene events for correlation with various other clinical factors, including differentiation status, sex, age and treatment response. We found Wnt pathway mutations had a strong association with well differentiated tumours (*P* = 0.001, OR = 2.9, Fisher's test, two-sided, see [Methods](#S8){ref-type="sec"}; [Fig. 5f](#F5){ref-type="fig"}). Female cases (*n* = 81) were enriched for *KRAS* mutation (*P* = 0.001, Fisher's exact test, two-sided) and *TP53* wild-type status (*P* = 0.006, Fisher's exact test, two-sided) ([Fig. 5g](#F5){ref-type="fig"}). This is of particular interest given the male predominance of EAC[@R3].

Targeted therapeutics using EAC driver events {#S6}
---------------------------------------------

To investigate whether driver events in particular genes and/or pathways might sensitize EAC cells to certain targeted therapeutic agents, we used the Cancer Biomarkers database[@R40]. We calculated the percentage of our cases that contain EAC-driver biomarkers of response to each drug class in the database ([Fig. 6a](#F6){ref-type="fig"}, and full data in [Supplementary Table 11](#SD1){ref-type="supplementary-material"}). Aside from TP53, which has been problematic to target clinically so far, we found a number of drugs with predicted sensitivity in \>10% of EACs, including EZH2 inhibitors for some SWI/SNF mutant cancers (23%, and 28% including all SWI/SNF EAC drivers), and BET inhibitors, which target *KRAS* activated and *MYC* amplified cases (25%). However, by far the most significantly effective drug was predicted to be CDK4/6 inhibitors, where \>50% of cases harbored sensitivity causing events in the receptor tyrosine kinase (RTK) and core cell cycle pathways (e.g. in *CCND1*, *CCND3* and *KRAS*).

To verify that these driver events would also sensitize EAC tumors to such inhibitors, we used a panel of 13 EAC or Barrett's high grade dysplasia cell lines that have undergone whole genome sequencing[@R41] and assessed them for presence of EAC driver events ([Fig. 6b](#F6){ref-type="fig"}). The mutational landscape of these lines was broadly representative of EAC tumors. We found that the presence of cell cycle and or RTK activating driver events was highly correlated with response to two FDA approved CDK4/6 inhibitors, Ribociclib and Palbociclib, and several cell lines were sensitive below maximum tolerated blood concentrations in humans ([Fig. 6b](#F6){ref-type="fig"}, [Supplementary Table 12](#SD1){ref-type="supplementary-material"}, and [Supplementary Fig. 12](#SD1){ref-type="supplementary-material"})[@R42]. Such EAC cell lines had comparable sensitivity to T47D, which is derived from an ER-positive breast cancer, where CDK4/6 inhibitors have been FDA approved. We noted three cell lines that were highly resistant, with little drug effect even at 4,000 nM concentrations, similar to a known Rb mutant resistant line breast cancer cell line (MDA-MB-468). Two of these three cell lines harbor amplification of *CCNE1*, which is known to drive resistance to CDK4/6 inhibitors by bypassing CDK4/6 and causing Rb phosphorylation via CDK2 activation[@R43]. To verify these effects in a more representative model of EAC, we treated three whole genome sequenced EAC organoid cultures[@R44] with Palbociclib and Ribociclib as well as a more recently approved CDK4/6 inhibitor, Abemaciclib. As was observed in cell lines, cell cycle and RTK driver events were present only in the more sensitive organoids and CCNE1 activation in the most resistant ([Fig. 6c](#F6){ref-type="fig"}).

Discussion {#S7}
==========

We present here a detailed catalog of coding and non-coding genomic events that have been selected for during the evolution of esophageal adenocarcinoma. These events have been characterized in terms of their relative impact, related functions, mutual exclusivity and co-occurrence and expression in comparison to normal tissues. We have used this set of biologically important gene alterations to identify prognostic biomarkers and actionable genomic events for personalized medicine.

While clinical annotation and matched RNA data is a strength of this study, in some cases we may have been unable to assess selected variants expression changes that were detected in the full 551 cohort due to lack of representation RNA matched sub-cohort. Despite rigorous analyses to detect selected events, assessment of the global excess of mutations by dNdScv suggests that we are unable to detect all mutations selected in EAC, similar to many other cancer types[@R21]. All driver gene detection methods that we have used rely on driver mutation re-occurrence in a genomic region to some degree. Many of these undetected driver mutations are hence likely to be spread across a large number of genes, whereby each is mutated at very low frequency across EAC patients. This tendency for low frequency EAC drivers may be responsible for the low yield of MutSigCV in previous cohorts and may suggests that C-type cancers such as EAC are not less 'mutation-driven' than M-type cancers but rather that their mutational drivers are spread across a larger number of genes[@R5]. Copy number driver gene identification is even more challenging due to the large size and lower frequency of these events, and hence it is also possible that there are significantly more EAC copy number drivers yet to discovered, possibly already identified as candidates here.

While a number of previous reports have attempted to detect EAC drivers, they have had a limited yield per case. The first such study[@R19] used methods that, despite being well regarded at the time, were subsequently discredited[@R8]. Since then, a number of reports, including our own, on medium and large cohort sizes using MutSigCV[@R9],[@R10],[@R17] were only able to detect a small number of mutational driver genes (7, 5 and 15 in each study). By using both a large cohort and more comprehensive methodologies, we have significantly increased this figure to 66 mutational driver genes (excluding copy number drivers). Detection of driver CNAs has previously relied on GISTIC to detect recurrently copy number aberrant regions[@R9],[@R14]--[@R17], but no analyses have been performed to determine which genes in these large regions are true drivers. Many of the genes annotated by such papers are unlikely to be copy number drivers due to their lack of expression modulation with CNAs (e.g. *YEATS4* and *MCL1*), the role of recurrent heterozygous losses to drive LOH in some mutational drivers (*ARID1A* and *CDH11*) or their association with fragile sites (*PDE4D*, *WWOX*, *FHIT*). Conversely, we have been able to identify novel EAC copy number drivers (e.g. *CCND3*, *AXIN1*, *PPM1D* and *APC*).

We have noted a three-way association between hyper-mutation, Wnt activation and loss of immune signalling genes such as *B2M*. MSI-driven hyper-mutation has been previously associated with higher immune activity[@R45],[@R46]. However, Wnt dysregulation and mutation of immune pathway genes such as *B2M*[@R33] have been previously linked to immune escape[@R47], suggesting this may be an acquired mechanism to prevent immune surveillance caused by hyper-mutation.

Functional characterization of many of the driver genes described is needed to understand why they are advantageous to EAC tumors and how they modify EAC biology. Biological pathways and processes that are selectively dysregulated deserve particular attention in this regard, as do the gene pairs or groups with mutually exclusive or co-occurring relationships such as *MYC* and *TP53* or SWI/SNF factors, suggestive of particular functional relationships. Prospective clinical work to verify and implement *SMAD4* and *GATA4* biomarkers in this study would be worthwhile. While EAC is a poor prognosis cancer type, significant heterogeneity of survival outcome makes triaging patients in treatment groups an important part of clinic practice, which could be improved using better prognostication. A number of targeted therapeutics may provide clinic benefit to EAC cases based on their individual genomic profile. In particular, CDK4/6 inhibitors deserve considerable attention as an option for EAC treatment as they are, by a significant margin, the treatment to which the most EACs harbor sensitivity-causing driver events, excluding TP53 as an unlikely therapeutic biomarker. Previous work has noted activity of the CDK4/6 inhibitor Palbociclib in a small number of EAC cell lines[@R48], but biomarkers were not investigated. The extensive *in vitro* validation of identified biomarkers for CDK4/6 inhibitors in EAC across 16 cell lines and organoids is persuasive of possible clinical benefit using a targeted approach.

In summary, this work provides a detailed compendium of mutations and copy number alterations undergoing selection in EAC, which have clinically relevant impact on tumor behaviour. This comprehensive study provides us with useful insights into the nature of EAC tumors and should pave the way for evidence based clinical trials in this poor prognosis disease.

Methods {#S8}
=======

Cohort, sequencing and calling of genomic events {#S9}
------------------------------------------------

379 cases (69%) of our EAC cohort were derived from the esophageal adenocarcinoma WGS ICGC study, for which samples are collected through the UK wide OCCAMS (Oesophageal Cancer Classification and Molecular Stratification) consortium. The procedures for obtaining the samples, quality control processes, extractions and whole genome sequencing are as previously described[@R17]. Strict pathology consensus review was observed for these samples with a 70% cellularity requirement before inclusion. Comprehensive clinical information was available for the ICGC-OCCAMS cases ([Supplementary Table 13](#SD1){ref-type="supplementary-material"}). In addition, previously published samples were included in the analysis from Dulak et al.[@R19] (149 WES; 27%) and Nones et al.[@R20] (22 WGS samples; 4%) to total 551 genome characterized EACs. RNA-seq data was available from our ICGC WGS samples (116/379). BAM files for all samples (include those from Dulak et al.[@R19] and Nones et al.[@R20]) were run through our alignment (BWA-MEM), mutation (Strelka), copy number (ASCAT) and structural variant (Manta) calling pipelines, as previously described[@R17]. Our methods were benchmarked against various other available methods and have among the best sensitivity and specificity for variant calling (ICGC benchmarking exercise[@R49],[@R50]). Cell lines were whole genome sequenced at 30X coverage with 150bp paired end reads on an Illumina Hiseq4000. Copy number calling was performed by Freec as previously described[@R41]. Mutations were called by GATK as previously described[@R41], filtered for germline variants in the 1000 genomes project and any known oncogenic hotspots[@R32] were recovered. Amplifications were defined as genes with 2x the median copy number of the host chromosome or greater.

Total RNA was extracted using All Prep DNA/RNA kit from Qiagen, and the quality was checked on Agilent 2100 Bioanalyzer using RNA 6000 nano kit (Agilent). Qubit High sensitivity RNA assay kit from Thermo Fisher was used for quantification. Libraries were prepared from 250 ng RNA, using TruSeq Stranded Total RNA Library Prep Gold (Ribo-zero) kit, and ribosomal RNA (nuclear, cytoplasmic and mitochondrial rRNA) was depleted, whereby biotinylated probes selectively bind to ribosomal RNA molecules forming probe-rRNA hybrids. These hybrids were pulled down using magnetic beads and rRNA depleted total RNA was reverse transcribed. The libraries were prepared according to Illumina protocol[@R51]. Paired end 75-bp sequencing on HiSeq4000 generated the paired end reads. For normal expression controls, we chose gastric cardia tissue, from which some hypothesize Barrett's esophagus may arise, and duodenum which contains intestinal histology, including goblet cells, which mimics that of Barrett's esophagus. We did not use Barrett's esophagus tissue itself as a normal control given the heterogeneous and plentiful phenotypic and genomic changes that it undergoes early in its pathogenesis.

Analyzing EAC mutations for selection {#S10}
-------------------------------------

To detect positively selected mutations in our EAC cohort, a multi-tool approach across various selection related 'features' (recurrence, functional impact, clustering) was implemented in order to provide a comprehensive analysis. This is broadly similar to several previous approaches[@R7],[@R11]. dNdScv[@R21], MutSigCV[@R8], e-Driver[@R25], ActivedriverWGS[@R22] and e-Driver3D[@R26] were run using the default parameters. To run OncodriverFM[@R23], Polyphen[@R52] and SIFT[@R53] were used to score the functional impact of each missense non-synonymous mutation (from 0 non-impactful to 1 highly impactful); synonymous mutations were given a score of 0 impact, and truncating mutations (nonsense and frameshift mutations) were given a score of 1. Any gene with less than 7 mutations, unlikely to contain detectable drivers using this method, was not considered to decrease the false discovery rate (FDR). OncodriveClust was run using a minimum cluster distance of 3, minimum number of mutations for a gene to be considered of 7 and with a stringent probability cut off to find cluster seeds of *P* = 1 x 10^-13^ to prevent infiltration of large numbers of, likely, false positive genes. For all tool outputs, we undertook quality control including Q-Q plots to ensure no tool produces inflated *q*-values and each tool produced at least 30% known cancer genes. Two tools were removed from the analysis due to failure for both of these parameters at quality control in our hands (Activedriver[@R54] and Hotspot[@R32]). For three of the QC-approved tools (dNdScv, OncodriveFM, MutSigCV) where this was possible, we also undertook an additional FDR reducing analysis by re-calculating *q* values based on analysis of known cancer genes only[@R21],[@R27],[@R28] as has been previously implemented[@R21],[@R55]. Significance cut offs were set at *q* \< 0.1 for coding genes. Tool outputs were then put through various filters to remove any further possible false positive genes. Specifically, genes where \<50% of EAC cases had no expression (TPM\<0.1) in our matched RNA-seq cohort were removed and, using dNdScv, genes with no or only a small mutation excess (observed: expected ratio \> 1.5:1) of any single mutation type were also removed. We also removed mitochondrial genes two (*MT-MD2*, *MT-MD4*) that were highly enriched for truncating mutations and were frequently called in OncodriveFM as well as other tools. This is may be due to the different mutational dynamics caused by ROS from the mitochondrial electron transport chain and the high number of mitochondrial genomes per cell, which enables significantly more heterogeneity. These factors prevent the tools used from calculating an accurate null model for these genes, but they may be worthy of functional investigation. ActiveDriverWGS calculates an expected background mutation rate based on mutation rates of local, adjacent sequence for each tested element while correcting for the differential mutation rates within each trinucleotide context. It thus tests observed mutation rates against this predicted background for each element. ActiveDriverWGS also detects elements with mutations enriched in binding site regions (high impact). For non-coding elements called by ActivedriverWGS, filtering for expression or dN/dS was not possible, and despite recent benchmarking[@R29], such methods are not so well established. Hence we took a more cautious approach with general significance cut offs of *q* \< 0.001 and *q* \< 0.1 for previously identified elements in other cancer types[@R11]. *q* values were not recalculated for previously identified elements alone like with coding genes, but the *q* \< 0.1 cut off was calculated based on *P* values for all assessed elements. To calculate exome-wide mutational excess, hyper-mutated cases (\>500 exonic mutations) were removed and the global non-synonymous dN/dS ratios were applied to all dNdScv annotated mutations excluding "synonymous" and "no SNV" annotations as described in Martincorena et al.[@R21].

Detecting selection in CNVs {#S11}
---------------------------

ASCAT raw copy number values were used to detected frequently deleted or amplified regions of the genome using GISTIC2.0[@R14]. To determine which genes in these regions confer a selective advantage, CNVs from each gene within GISTIC identified loci were correlated with TPM from matched RNA-seq in a sub-cohort of 116 samples and with mutations across all 551 samples. To call copy number in genes that spanned multiple copy number segments in ASCAT, we considered the total number of full copies of the gene (i.e. the lowest total copy number). Occasionally ASCAT is unable to confidently call the copy number in highly aberrant genomic regions. We found that the expression of genes in such regions matched well what we would expect given the surrounding copy number, and hence we used the mean of the two adjacent copy number fragments to call copy number in the gene in question. We found amplification peak regions identified by GISTIC2.0 varied significantly in precise location both in analysis of different sub-cohorts and when comparing to published GISTIC data from EACs[@R9],[@R15],[@R16]. A peak would often sit next to but not overlapping a well-characterized oncogene or tumor suppressor. To account for this, we widened the amplification peak sizes upstream and downstream by twice the size of each peak to ensure we captured all possible drivers. Our expression analysis allows us to then remove false positives from this wider region, and called drivers were still highly enriched for genes closer to the centre of GISTIC peak regions.

To detect genes in which amplification correlated with increased expression, we compared expression of samples with a high copy number for that gene (above 10^th^ percentile CN/ploidy) with those that have a normal copy number (median +/- 1) using the Wilcoxon rank-sum test and using the specific alternative hypothesis that high copy number would lead to increased expression. *q*-values were then generated based on the Benjamini and Hochberg method, not considering genes without significant expression in amplified samples (at least 75% amplified samples with TPM \> 0.1) and considering *q* \< 0.001 as significant. We also included an additional known driver gene only FDR reduction analysis as previously described for mutational drivers, with *q* \< 0.1 considered as significant given the additional evidence for these genes in other cancer types. We also included *MYC* despite its *P* = 0.11 for expression correlation. This is due to frequent non-amplification associated overexpression of *MYC* when compared to normal controls, and otherwise *MYC* is well evidenced by a very close proximity to the peak centre (top 4 genes) and its high rate of amplification (19%). We took the same approach to detect genes in which homozygous deletion correlated with expression loss, comparing cases with copy number = 0 to all others. Large expression modulation was a highly specific marker for known copy number driver genes and was not a widespread feature in most recurrently copy number variant genes. However, while expression modulation is a requirement for selection of CNV only drivers, it is not sufficient evidence alone, and hence we grouped such genes into those which have been characterized as drivers previously in other cancer types (high confidence EAC copy number drivers) and other genes (candidate EAC copy number drivers), which await functional validation. We used fragile site regions detected in Wala et al.[@R56]. We also defined regions that may be recurrently heterozygous deleted, without any significant expression modulations, to allow LOH of tumor suppressor gene mutations. To do this, we analyzed genes with at least 5 mutations for association between LOH (ASCAT minor allele = 0) and mutation using Fisher's exact test and generated *q* values using the Benjamini and Hochberg method. The analysis was repeated on known cancer genes only for reduced FDR and *q* \< 0.1 considered significant for both analyses. For those high confidence drivers, we chose to define amplification as total copy number/ploidy (referred to as ploidy adjusted copy number) because this produces superior correlation with expression. We chose a cut off for amplification at ploidy adjusted copy number = 2 as has been previously used, and causes a highly significant increase in expression in our copy number-driver genes when amplified.

Pathways and relative distributions of genomic events {#S12}
-----------------------------------------------------

The relative distribution of driver events in each pathway was analysed using a Fisher's exact test in the case of pair-wise comparisons including wild-type cases. In the case of multi-gene comparisons such as cyclins, we calculate the *P* value and odds ratio for gene in the group using a two-sided Fisher's exact test, corrected by Benjamini and Hochberg, and combine resulting *q* values using the Fisher method; genes without odds ratios \> 2 for co-occurrence and \< 0.5 for mutual exclusivity were removed. For this analysis, we also remove highly mutated cases (\>500 exonic mutations, 41/551) as they bias distribution of genes towards co-occurrence. To ensure that a non-random distribution of mutations across samples was still not affecting the strong co-occurrence of SWI/SNF genes (all genes *q* \< 0.05 before combining *q* values), we repeated the analysis randomly iterating 30,000 times over other driver gene eight combinations (excluding SWI/SNF genes) and found only 0.01% (4/30,000) of random combinations had all genes *q* \< 0.05 as found in SWI/SNF genes. We then performed this analyses across all pairs of driver genes using two sided Fisher's exact tests and Benjamini and Hochberg multiple hypothesis correction (*q* values \< 0.1 are shown in [Fig. 4b](#F4){ref-type="fig"}). We validated these relationships in independent TGCA cohorts of other GI cancers where we could find cohorts with reasonable numbers of the genomic events in question (not possible for *GATA4*/*GATA6*, for instance) using the cBioportal web interface tool[@R57].

Correlating genomics with the clinical phenotype {#S13}
------------------------------------------------

To find genomic markers for prognosis, we undertook univariate Cox regression for those driver genes present in \>5% of cases (*n* = 16) along with Benjamini and Hochberg false discovery correction. We considered only these genes to reduce our false discovery rate and because other genes were unlikely to impact on clinical practice given their low frequency in EAC. We validated *SMAD4* in the TCGA gastroesophageal cohort, which had a comparable frequency of these events, but notably is composed mainly of gastric cancers, and *GATA4* in the TCGA pancreatic cohort using the cBioportal web interface tool. We also validated these markers as independent predictors of survival both in respect of each other and stage using a multivariate Cox regression in our 379 clinical annotated ICGC cohort. When assessing for genomic correlates with differentiation phenotypes, we found only very few cases with well differentiated phenotypes (\<5% cases), and hence for statistical analyses, we collapse these cases with moderate differentiation to allow a binary Fisher's exact test to compare poorly differentiated with well-moderate differentiated phenotypes.

Therapeutics {#S14}
------------

The cancer biomarker database was filtered for drugs linked to biomarkers found in EAC drivers, and [Supplementary Table 8](#SD1){ref-type="supplementary-material"} was constructed using the cohort frequencies of EAC biomarkers. Ten EAC cell lines (SKGT4, OACP4C, OACM5.1, ESO26, ESO51, OE33, MFD, OE19, Flo-1 and JHesoAD) and three Barrett's esophagus high grade dysplasia cell lines (CP-B, CP-C and CP-D) with WGS data[@R41] were used in proliferation assays to determine drug sensitivity to CDK4/6 inhibitors, Palbociclib (Biovision) and Ribociclib (Selleckchem). Cell lines were grown in their normal growth media. Proliferation was measured using the Incucyte live cell analysis system (Incucyte ZOOM Essen biosciences). Each cell line was plated at a starting confluency of 10% and growth rate measured across 4-7 days depending on basal proliferation rate (until 90% confluent). For each cell-line drug combination, concentrations of 16, 64, 250, 1,000 and 4,000 nM were used each in 0.3% DMSO and compared to 0.3% DMSO only. Each condition was performed in at least triplicate (technical replicates) and 12/12 randomly chosen cell line; drug combinations were successfully replicated with biological replicates (independent experiments). The time period of treatment to growth cessation in the control (0.3% DMSO) condition was used to calculate GI50 and AUC. Accurate GI50s could not be calculated in cases where a cell line had \>50% proliferation inhibition even with the highest drug concentration, and hence AUC was used to compare cell line sensitivity. T47D had a highly similar GI50 for Palbociclib to that previously calculated in other studies (112 nM vs. 127 nM)[@R58]. Primary organoid cultures were derived from EAC cases included in the OCCAMS/ICGC sequencing study. Detailed organoid culture and derivation method have been previously described[@R44]. Regarding the drug treatment, the seeding density for each organoid line was optimized to ensure cell growth in the logarithmic growth phase. Cells were seeded in complete medium for 24 hours then treated with compounds at 5-point 4-fold serial dilutions for 6 days or 12 days. Cell viability was assessed using CellTiter-Glo (Promega) after drug incubation.
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###### Editorial summary

Genomic analysis of 551 esophageal adenocarcinomas identifies new driver mutations and biomarkers associated with poor prognosis. Over 50% of esophageal adenocarcinomas contain sensitizing events for CDK4/6 inhibitors, providing an evidence base for targeted therapeutics.

![Detection of EAC driver genes.\
**a**, Types of driver-associated features used to detect positive selection in mutations and copy number events with examples of genes containing such features. **b**, Coding driver genes identified and their driver-associated features. **c**, Non-coding driver elements detected and their element types.](emss-80842-f001){#F1}

![Copy number variation under positive selection.\
a, Recurrent copy number changes across the genome identified by GISTIC in 551 EACs. Frequency of different CNV types are indicated (dark blue, homozygous deletion; light blue, heterozygous deletion; dark red, extrachromosomal-like amplification; light red, amplification) as well as the position of CNV high confidence driver genes and candidate driver genes. The *q* value for expression correlation with amplification and homozygous deletion is shown for each gene within each amplification (wilcox test, one sided, expression compared above and below 90th percentile of pliody-adjusted CN) and deletion peak (wilcox test, one sided, expression compared between homozygous deleted and all other cases) respectively and occasions of significant association between LOH and mutation are indicated in green (fisher's exact test, one sided). Benjamini & Hochberg false discovery correction was applied in each of these cases. Purple deletion peaks indicate fragile sites. b, Examples of extrachromosomal-like amplifications suggested by very high read support SVs at the boundaries of highly amplified regions produced from a single copy number step. In the first example two populations of extrachromosomal DNA are apparent, one amplifying only MYC and the second also incorporating ERBB2 from a different chromosome. In the second example an inversion has occurred before circularization and amplification around KRAS. c, Relationship between copy number and expression in copy number driver genes in RNA matched sub-cohort (n=116). A 2D kernel density estimation and a leoss regression curve with 95% CIs (grey) are shown to describe the data.](emss-80842-f002){#F2}

![The driver gene landscape of EAC.\
**a**, Driver mutations or CNVs are shown for each patient of 551 EACs. Amplification is defined as \>2 copy number adjusted ploidy (2x ploidy of that case) and extrachromosomal amplification as \>10 copy number adjusted ploidy (10x ploidy for that case). Driver associated features for each driver gene are displayed to the left. On the right, the percentages of different mutation and copy number changes are displayed, differentiating between driver and passenger mutations using dNdScv, and the % of predicted drivers by mutation type is shown. Above the plot are the number of driver mutations per sample with an indication of the mean (red line = 5). **b**, Mean driver events per case in 551 EACsand comparison to exome-wide excess of mutations generated by dNdScv. **c**, Expression changes in EAC driver genes in comparison to normal intestinal tissues in RNA matched samples (n=116). Only genes with expression changes of note are shown.](emss-80842-f003){#F3}

![Biological pathways undergoing selective dysregulation in EAC.\
**a**, Biological pathways dysregulated by driver gene mutation and/or CNVs in 551 cases. Wild-type cases for a pathway are not shown. Inter and intra-pathway interactions are described, and mutual exclusivities and/or associations between genes in a pathway are annotated. *GATA4* and *GATA6* amplifications have a mutually exclusive relationship, although this does not reach statistical significance (Fisher's exact test, two-sided, *P* = 0.07, OR = 0.52). **b**, Pairwise assessment of mutual exclusivity and association in EAC driver genes and pathways. Two sided Fisher's exact test were used and hyper-mutated (\>500 exonic mutations) cases were removed to avoid bias towards co-occurrence, hence n = 510. RTK; Receptor Tyrosine Kinase pathway.](emss-80842-f004){#F4}

![Clinical significance of driver events in 379 clinically annotated EACs.\
**a**, Hazard ratios and 95% confidence intervals for Cox regression analysis across all driver genes with at least a 5% frequency of driver alterations. \**q* \< 0.05 after BH adjustment. **b**, Kaplan-Meier curves for EACs with different status of significant prognostic indicators (*GATA4* and *SMAD4*). **c**, Kaplan-Meier curves for different alterations in the TGF-β pathway. **d**, Kaplan-Meier curves showing verification *GATA4* prognostic value in GI cancers using a pancreatic TCGA cohort. **e**, Kaplan-Meier curves showing verification *SMAD4* prognostic value in gastroesophageal cancers using a gastroesophageal TCGA cohort. **f**, Differentiation bias in tumors containing events in Wnt pathway driver genes. **g**, Relative frequency of *KRAS* mutations and *TP53* mutations driver gene events in females vs. males (Fisher's exact test, two sided).](emss-80842-f005){#F5}

![CDK4/6 inhibitors in EAC.\
**a**, Drug classes for which sensitivity is indicated by EAC driver genes with data from the Cancer Biomarkers database[@R36]. **b**, Area under the curve (AUC) of sensitivity is shown in a panel of 13 EAC and Barrett's esophagus high grade dysplasia cell lines with associated WGS and their corresponding driver events, based on primary tumor analysis. AUC is also shown for two control lines: T47D, an ER-positive breast cancer line (positive control), and MDA-MB-468, an Rb negative breast cancer (negative control). \**CCNE1* is a known marker of resistance to CDK4/6 inhibitors due to its regulation of Rb downstream of CDK4/6, hence bypassing the need for CDK4/6 activity (see [Fig. 4](#F4){ref-type="fig"}). **c**, Response of organoid cultures to three FDA approved CDK4/6 inhibitors and corresponding driver events. RTK; Receptor tyrosine kinase pathway, BC; Breast Cancer.](emss-80842-f006){#F6}
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